Market Place
Sourcing Support
Porton Shanghai Site Clears EU QP Audit
19 Jun 2025 //
PRESS RELEASE
Porton Sets 2030 Sustainability Targets on Environment Day
05 Jun 2025 //
PRESS RELEASE
Porton Conquers Complex POC Project With Innovation
26 May 2025 //
PRESS RELEASE
Porton to Showcase Integrated CDMO Expertise at BOS Basel 2025
23 May 2025 //
PRESS RELEASE
Porton Advance recieves IND Approval for Tasly’s CAR-T Therapy
16 Apr 2025 //
PRESS RELEASE
Porton Showcases Innovation At Key Industry Events &Expert Forums
13 Feb 2025 //
PRESS RELEASE
Porton Achieves Higher Scores in the 2024 S & P Global ESG Assessment
01 Jan 2025 //
PRESS RELEASE
Porton Pharma Earns Sustainability Acclaim Among Chinese Firms
06 Dec 2024 //
PRESS RELEASE
Porton Pharma Launches Refreshed Official Website
06 Dec 2024 //
PRESS RELEASE
Proton At CPhI North America Again
16 May 2024 //
PRESS RELEASE
Upcoming Porton Shows In Europe And The USA：Shaping Our Future Together
19 Apr 2024 //
PRESS RELEASE
Porton Makes Debut At DCAT Week 2024
28 Mar 2024 //
PRESS RELEASE
Porton Pharma Solutions Joined The SBTi To Drive Climate Action
02 Mar 2024 //
PRESS RELEASE
PCS Is Held Annually To Bring Together Developers Of New Medicines
28 Sep 2023 //
PRESS RELEASE
Dr. Angelo Maria Manzo of Porton Pharma Solutions Joins BOS Basel 2023, Spearheading Collaborations
19 Jun 2023 //
PRESS RELEASE
Porton Pharma Solutions Launches State-of-the-Art Small Molecule Platform in Shanghai, Elevating CDMO Services
19 Jun 2023 //
PRESS RELEASE
Porton Pharma Solutions Expands Global Reach with New Site in Slovenia and Enhanced Manufacturing Capabilities
19 Jun 2023 //
PRESS RELEASE
Porton Unveils Its Small Molecule Platform Headquarters In Shanghai
14 May 2023 //
PRESS RELEASE
Porton Released 2022 CSR Report
25 Mar 2023 //
PRESS RELEASE
Porton Pharma Solutions Recognized by Roche Group as a Leading CDMO Service Provider
16 Dec 2022 //
PRESS RELEASE
Porton Reports Strong Interim Results 2022
23 Aug 2022 //
PRESS RELEASE
Porton raises funds for gene and cell therapy CDMO platforms expansion
23 Aug 2022 //
PHARMACEUTICAL-TECHNOLOGY
How to Choose the Right Cell and Gene Therapy CDMO
02 May 2022 //
GENENGNEWS
Porton Announced To Acquire China Gateway Pharmaceutical Development
11 Mar 2022 //
PRESS RELEASE
Porton Expects Strongly Growth In Revenue And Net Profit In 2021
10 Jan 2022 //
PRESS RELEASE
Porton Announces Acquisition Of Yuyang Pharmaceutical To Expand Its Manufacturing Capacity
18 Aug 2021 //
PRESS RELEASE
CfPC Announces Program Of 2021 Pharmaceutical Crystallization Summit(Reproduced)
24 Jun 2021 //
PRESS RELEASE
Porton Biologics Announces Closing Series-A Financing To Drive Commercial Production Of Gene And Cell Therapy
16 Apr 2021 //
PRESS RELEASE
Porton Launches An Integrated CGMP Solutions Suite At Its Chongqing Process Technology Center, China
21 May 2020 //
PRESS RELEASE
Porton Successfully Receives Third US FDA Inspection.
21 Apr 2020 //
PRESS RELEASE
Porton’s Successfully Executes Process Validation Of A Major NCE Drug For A Global Pharmaceutical Company
08 Apr 2020 //
PRESS RELEASE
CDMO PharmaBlock purchases Chinese facility to meet increasing demand
02 Oct 2018 //
OUTSOURCING-PHARMA
Porton Pharma Solutions and Codexis launch global partnership
27 Apr 2018 //
EUROPEANPHARMACEUTICAL REVIEW
Codexis and Porton Pharma announce strategic collaboration
23 Apr 2018 //
THEFLY
